Bone pain: current and future treatments

Charlotte Ørsted Frost; Rikke Rie Hansen; Anne-Marie Heegaard

doi:10.1016/j.coph.2016.02.007

Bone pain: current and future treatments

Charlotte Ørsted Frost, Rikke Rie Hansen, Anne-Marie Heegaard

9 Citations (Scopus)

Abstract

Skeletal conditions are common causes of chronic pain and there is an unmet medical need for improved treatment options. Bone pain is currently managed with disease modifying agents and/or analgesics depending on the condition. Disease modifying agents affect the underlying pathophysiology of the disease and reduce as a secondary effect bone pain. Antiresorptive and anabolic agents, such as bisphosphonates and intermittent parathyroid hormone (1-34), respectively, have proven effective as pain relieving agents. Cathepsin K inhibitors and anti-sclerostin antibodies hold, due to their disease modifying effects, promise of a pain relieving effect. NSAIDs and opioids are widely employed in the treatment of bone pain. However, recent preclinical findings demonstrating a unique neuronal innervation of bone tissue and sprouting of sensory nerve fibers open for new treatment possibilities.

Original language	English
Journal	Current Opinion in Pharmacology
Volume	28
Pages (from-to)	31-7
Number of pages	7
ISSN	1471-4892
DOIs	https://doi.org/10.1016/j.coph.2016.02.007
Publication status	Published - 1 Jun 2016

Keywords

Journal Article
Review

Access to Document

10.1016/j.coph.2016.02.007

Cite this

@article{5ee67df6018143269844be8586d04d7c,

title = "Bone pain: current and future treatments",

abstract = "Skeletal conditions are common causes of chronic pain and there is an unmet medical need for improved treatment options. Bone pain is currently managed with disease modifying agents and/or analgesics depending on the condition. Disease modifying agents affect the underlying pathophysiology of the disease and reduce as a secondary effect bone pain. Antiresorptive and anabolic agents, such as bisphosphonates and intermittent parathyroid hormone (1-34), respectively, have proven effective as pain relieving agents. Cathepsin K inhibitors and anti-sclerostin antibodies hold, due to their disease modifying effects, promise of a pain relieving effect. NSAIDs and opioids are widely employed in the treatment of bone pain. However, recent preclinical findings demonstrating a unique neuronal innervation of bone tissue and sprouting of sensory nerve fibers open for new treatment possibilities.",

keywords = "Journal Article, Review",

author = "Frost, {Charlotte {\O}rsted} and Hansen, {Rikke Rie} and Anne-Marie Heegaard",

year = "2016",

month = jun,

day = "1",

doi = "10.1016/j.coph.2016.02.007",

language = "English",

volume = "28",

pages = "31--7",

journal = "Current Opinion in Pharmacology",

issn = "1471-4892",

publisher = "Elsevier Ltd. * Current Opinion Journals",

}

TY - JOUR

T1 - Bone pain

T2 - current and future treatments

AU - Frost, Charlotte Ørsted

AU - Hansen, Rikke Rie

AU - Heegaard, Anne-Marie

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Skeletal conditions are common causes of chronic pain and there is an unmet medical need for improved treatment options. Bone pain is currently managed with disease modifying agents and/or analgesics depending on the condition. Disease modifying agents affect the underlying pathophysiology of the disease and reduce as a secondary effect bone pain. Antiresorptive and anabolic agents, such as bisphosphonates and intermittent parathyroid hormone (1-34), respectively, have proven effective as pain relieving agents. Cathepsin K inhibitors and anti-sclerostin antibodies hold, due to their disease modifying effects, promise of a pain relieving effect. NSAIDs and opioids are widely employed in the treatment of bone pain. However, recent preclinical findings demonstrating a unique neuronal innervation of bone tissue and sprouting of sensory nerve fibers open for new treatment possibilities.

AB - Skeletal conditions are common causes of chronic pain and there is an unmet medical need for improved treatment options. Bone pain is currently managed with disease modifying agents and/or analgesics depending on the condition. Disease modifying agents affect the underlying pathophysiology of the disease and reduce as a secondary effect bone pain. Antiresorptive and anabolic agents, such as bisphosphonates and intermittent parathyroid hormone (1-34), respectively, have proven effective as pain relieving agents. Cathepsin K inhibitors and anti-sclerostin antibodies hold, due to their disease modifying effects, promise of a pain relieving effect. NSAIDs and opioids are widely employed in the treatment of bone pain. However, recent preclinical findings demonstrating a unique neuronal innervation of bone tissue and sprouting of sensory nerve fibers open for new treatment possibilities.

KW - Journal Article

KW - Review

U2 - 10.1016/j.coph.2016.02.007

DO - 10.1016/j.coph.2016.02.007

M3 - Journal article

C2 - 26940053

SN - 1471-4892

VL - 28

SP - 31

EP - 37

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

ER -

Bone pain: current and future treatments

Abstract

Keywords

Access to Document

Fingerprint

Cite this